Literature DB >> 25002031

Practice variation in defining sentinel lymph nodes on lymphoscintigrams in oral cancer patients.

Géke B Flach1, Annelies van Schie, Birgit I Witte, Renato A Valdés Olmos, W Martin C Klop, Otto S Hoekstra, Remco de Bree.   

Abstract

PURPOSE: Lymphoscintigraphic imaging and adequate interpretation of the lymphatic drainage pattern is an essential step in the sentinel lymph node biopsy (SLNB) procedure. In oral cancer, identification of the sentinel lymph node (SLN) can be challenging. In this study, interobserver variability in defining SLNs on lymphoscintigrams was evaluated in patients with T1-T2 stage N0 oral cancer.
METHODS: Sixteen observers (head and neck surgeons, nuclear medicine physicians or teams of both) from various institutes were asked which criteria they use to consider a hot focus on the lymphoscintigram as SLN. Lymphoscintigrams of 9 patients with 47 hot foci (3-9 per patient) were assessed, using a scale of 'yes/equivocal/no'. Bilateral drainage was seen in four of nine cases. In three cases additional late single photon emission computed tomography (SPECT)/CT scanning was performed. Interobserver variability was evaluated by kappa (к) analysis, using linear weighted pairwise comparison of the observers. Conservative (equivocal analysed as no) and sensitive (equivocal analysed as yes) assessment strategies were investigated using pairwise kappa analysis.
RESULTS: Various definitions of SLN on lymphoscintigrams were given. Interobserver variability of all cases using a 3-point scale showed fair agreement (71%, к(w) = 0.29). The conservative and sensitive analyses both showed moderate agreement: conservative approach к = 0.44 (in 80% of the hot foci the observers agreed) and sensitive approach к = 0.42 (81%) respectively. Multidisciplinary involvement in image interpretation and higher levels of observer experience appeared to increase agreement.
CONCLUSION: Among 16 observers, there is practice variation in defining SLNs on lymphoscintigrams in oral cancer patients. Interobserver variability of lymphoscintigraphic interpretation shows moderate agreement. In order to achieve better agreement in defining SLNs on lymphoscintigrams specific guidelines are warranted.

Entities:  

Mesh:

Year:  2014        PMID: 25002031     DOI: 10.1007/s00259-014-2843-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  16 in total

1.  The First International Conference on Sentinel Node Biopsy in Mucosal Head and Neck Cancer and adoption of a multicenter trial protocol.

Authors:  G L Ross; T Shoaib; D S Soutar; D G MacDonald; I G Camilleri; R G Bessent; H W Gray
Journal:  Ann Surg Oncol       Date:  2002-05       Impact factor: 5.344

2.  Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0.

Authors:  Naomi Alazraki; Edwin C Glass; Frank Castronovo; Renato A Valdés Olmos; Donald Podoloff
Journal:  J Nucl Med       Date:  2002-10       Impact factor: 10.057

3.  Sentinel lymph node biopsy in oral cancer: validation of technique and clinical implications of added oblique planar lymphoscintigraphy and/or tomography.

Authors:  J B Thomsen; J A Sørensen; P Grupe; A Krogdahl
Journal:  Acta Radiol       Date:  2005-10       Impact factor: 1.990

4.  Function, postoperative morbidity, and quality of life after cervical sentinel node biopsy and after selective neck dissection.

Authors:  Franziska Schiefke; Michael Akdemir; Anette Weber; Daniel Akdemir; Susanne Singer; Bernhard Frerich
Journal:  Head Neck       Date:  2009-04       Impact factor: 3.147

Review 5.  Sentinel node biopsy for squamous cell carcinoma of the oral cavity and oropharynx: a diagnostic meta-analysis.

Authors:  Tim M Govers; Gerjon Hannink; Matthias A W Merkx; Robert P Takes; Maroeska M Rovers
Journal:  Oral Oncol       Date:  2013-05-13       Impact factor: 5.337

6.  Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial.

Authors:  Francisco J Civantos; Robert P Zitsch; David E Schuller; Amit Agrawal; Russell B Smith; Richard Nason; Guy Petruzelli; Christine G Gourin; Richard J Wong; Robert L Ferris; Adel El Naggar; John A Ridge; Randal C Paniello; Kouros Owzar; Linda McCall; Douglas B Chepeha; Wendell G Yarbrough; Jeffrey N Myers
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

7.  Visualization of the sentinel node in early-stage oral cancer: limited value of late static lymphoscintigraphy.

Authors:  Derrek A Heuveling; Géke B Flach; Annelies van Schie; Stijn van Weert; K Hakki Karagozoglu; Elisabeth Bloemena; C René Leemans; Remco de Bree
Journal:  Nucl Med Commun       Date:  2012-10       Impact factor: 1.690

8.  Long-term experience in sentinel node biopsy for early oral and oropharyngeal squamous cell carcinoma.

Authors:  Martina A Broglie; Sarah R Haile; Sandro J Stoeckli
Journal:  Ann Surg Oncol       Date:  2011-05-19       Impact factor: 5.344

9.  Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma.

Authors:  Lee W T Alkureishi; Zeynep Burak; Julio A Alvarez; James Ballinger; Anders Bilde; Alan J Britten; Luca Calabrese; Carlo Chiesa; Arturo Chiti; Remco de Bree; Harry W Gray; Keith Hunter; Adorjan F Kovacs; Michael Lassmann; C Rene Leemans; Gerard Mamelle; Mark McGurk; Jann Mortensen; Tito Poli; Taimur Shoaib; Philip Sloan; Jens A Sorensen; Sandro J Stoeckli; Jorn B Thomsen; Giusepe Trifiro; Jochen Werner; Gary L Ross
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11       Impact factor: 9.236

10.  How many sentinel nodes should be harvested in oral squamous cell carcinoma?

Authors:  Timo Atula; Taimur Shoaib; Gary L Ross; Henry W Gray; David S Soutar
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-12-19       Impact factor: 2.503

View more
  6 in total

Review 1.  Sentinel lymph node biopsy in oral and oropharyngeal squamous cell carcinoma: current status and unresolved challenges.

Authors:  Christina Bluemel; Domenico Rubello; Patrick M Colletti; Remco de Bree; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-28       Impact factor: 9.236

2.  Within-patient comparison between [68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy and [99mTc]Tc-tilmanocept lymphoscintigraphy for sentinel lymph node detection in oral cancer: a pilot study.

Authors:  Rutger Mahieu; Dominique N V Donders; Gerard C Krijger; F F Tessa Ververs; Remmert de Roos; John L M M Bemelmans; Rob van Rooij; Remco de Bree; Bart de Keizer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-28       Impact factor: 10.057

3.  The added value of SPECT-CT for the identification of sentinel lymph nodes in early stage oral cancer.

Authors:  Inne J den Toom; Annelies van Schie; Stijn van Weert; K Hakki Karagozoglu; Elisabeth Bloemena; Otto S Hoekstra; Remco de Bree
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-29       Impact factor: 9.236

4.  Evaluation of a streamlined sentinel lymph-node imaging protocol in early-stage oral cancer.

Authors:  Michiel Zeeuw; Rutger Mahieu; Bart de Keizer; Remco de Bree
Journal:  Ann Nucl Med       Date:  2021-09-13       Impact factor: 2.668

5.  Additional non-sentinel lymph node metastases in early oral cancer patients with positive sentinel lymph nodes.

Authors:  Inne J Den Toom; Elisabeth Bloemena; Stijn van Weert; K Hakki Karagozoglu; Otto S Hoekstra; Remco de Bree
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-25       Impact factor: 2.503

6.  Sentinel lymph node detection in oral cancer: a within-patient comparison between [99mTc]Tc-tilmanocept and [99mTc]Tc-nanocolloid.

Authors:  Inne J den Toom; Rutger Mahieu; Rob van Rooij; Robert J J van Es; Monique G G Hobbelink; Gerard C Krijger; Bernard M Tijink; Bart de Keizer; Remco de Bree
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-25       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.